NEW YORK, Dec. 07, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cempra, Inc. (NASDAQ:CEMP) between October 22, 2015 and November 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Middle District of North Carolina. To get more information go to:
http://www.zlk.com/pslra/cempra-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Cempra made false and/or misleading statements and/or failed to disclose that: (i) Cempra’s lead product candidate solithromycin posed significant safety risks for hepatotoxicity; and (ii) as a result of the foregoing, Cempra’s public statements were materially false and misleading at all relevant times.
On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review of solithromycin, highlighting a significant safety signal for hepatotoxicity. Upon this news, shares of Cempra fell over 60% during intraday trading.
If you suffered a loss in Cempra you have until January 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Apple Turns 50: From Garage Startup to AI Crossroads
First Western Ship Transits Strait of Hormuz Since Iran War Began
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 



